Diagnostic biosensor quickly detects SARS-CoV-2 from nasopharyngeal swabs
A new test quickly detects SARS-CoV-2 (spheres) through binding to antibodies (Y-shapes) on a field-effect transistor. Credit: Adapted from ACS Nano 2020, DOI: 10.1021/acsnano.0c02823
Currently, most diagnostic tests for COVID-19 rely on a technique called real-time reverse transcription-polymerase chain reaction (RT-PCR), which amplifies SARS-CoV-2 RNA from patient swabs so that tiny amounts of the virus can be detected.
However, the method takes at least 3 hours, including a step to prepare the viral RNA for analysis.
Edmond Changkyun Park, Seung Il Kim and colleagues wanted to develop a faster diagnostic test that could analyze patient samples directly from a tube of buffer containing the swabs, without any sample preparation steps.
The team based their test on a field-effect transistor — a sheet of graphene with high electronic conductivity. The researchers attached antibodies against the SARS-CoV-2 spike protein to the graphene.
When they added either purified spike protein or cultured SARS-CoV-2 virus to the sensor, binding to the antibody caused a change in the electrical current.
Next, the team tested the technique on nasopharyngeal swabs collected from patients with COVID-19 or healthy controls. Without any sample preparation, the sensor could discriminate between samples from sick and healthy patients.
The new test was about 2-4 times less sensitive than RT-PCR, but different materials could be explored to improve the signal-to-noise ratio, the researchers say.
###
The authors acknowledge funding from the National Research Council of Science and Technology funded by the Ministry of Science and ICT, Korea and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute funded by the Ministry of Health & Welfare, Korea.
The abstract that accompanies this paper can be viewed here.
The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS' mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. The Society is a global leader in providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a specialist in scientific information solutions (including SciFinder® and STN®), its CAS division powers global research, discovery and innovation. ACS' main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.
Media Contact
All latest news from the category: Life Sciences and Chemistry
Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.
Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.
Newest articles
How marine worms regenerate lost body parts
The return of cells to a stem cell-like state as the key to regeneration. Many living organisms are able to regenerate damaged or lost tissue, but why some are particularly…
Nano-scale molecular detective
New on-chip device uses exotic light rays in 2D material to detect molecules. Researchers have developed a highly sensitive detector for identifying molecules via their infrared vibrational “fingerprint”. Published in Nature…
Novel CAR T-cell therapy
… demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors. The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors….